Mather, Omar

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 1,849

Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors

Ramalingam, S., Fakih, M., Strickler, J., Govindan, R., Li, B. T., Goldberg, S., Gandara, D., Burns, T., Barve, M., Shu, C., et al. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 40

434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)

Fakih, M., Falchook, G. S., Hong, D. S., Yaeger, R. D., Chan, E., Mather, O., Cardona, P., Dai, T., & Strickler, J. (2021) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 25

Abstract P05-02: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)

Gandara, D., Marrone, K., Govindan, R., Skoulidis, F., Durm, G., Clarke, J., Frank, R., Krauss, J., Snyder, W., Dai, T., et al. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 24

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects

Trivedi, A., Mather, O., Vega, S., Hutton, S., Hellawell, J., & Lee, E. (2022) · Drugs in R&D

Apelin-related biomedical researchHeart Failure Treatment and Management

Cited by 10